Communiqués Amplia Therapeutics Limited

Actions

ATX

AU0000023822

Recherche biotechnologique et médicale

Temps Différé Australian S.E. Autres places de cotation 06:01:33 26/06/2026			Varia. 5j.	Varia. 1 janv.
0,1300 ^AUD	-3,70%		+13,04%	-13,33%

25/06	Amplia Therapeutics indique que Washington H. Soul Pattinson devient actionnaire important	MT
24/06	Amplia Therapeutics annonce que Pengana Capital devient un actionnaire important	MT

Communiqués

22/06	Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer	GL
19/05	Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib	GL
09/05	Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study	GL
22/04	Accent Trial Mature Data Presented at International Conference	GL
23/03	Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial	GL
11/03	Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th	AQ
09/03	Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models	GL
11/02	Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial	GL
30/01	Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025	GL
22/01	NARMAFOTINIB Large-Scale Manufactre Complete	GL
12/01	ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM	GL
23/12	Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium	GL
19/12	Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors	GL
12/12	Additional Confirmed Response Reported as Part of Amplia Investor Presentation	GL
08/12	Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
03/12	Key Narmafotinib Patent Granted in the U.S.	GL
14/02/24	Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial	AQ
22/05/23	Amplia secures funding to assess AMP945 topical applications	AQ
30/01/23	Amplia Therapeutics CEO outlines 2023 milestones	AQ
28/07/22	Amplia Therapeutics : Quarterly Activities and Cashflow Reports - June 2022 Qtr	PU
22/07/22	Amplia Therapeutics : Notice of Annual General Meeting/Proxy - YE 31 March 2022	PU
30/06/22	Amplia Therapeutics : Application for quotation of securities - ATX	PU
09/06/22	Amplia Therapeutics : Application for quotation of securities - ATX	PU
30/05/22	Amplia Therapeutics : 2022 Corporate Governance Statement	PU
19/04/22	Amplia Therapeutics : Quarterly Activities and Cashflow Reports - March 2022 Qtr	PU